VRTX Jan 2025 270.000 call
| Previous close | 112.70 |
| Open | 112.70 |
| Bid | 113.00 |
| Ask | 123.00 |
| Strike | 270.00 |
| Expiry date | 2025-01-17 |
| Day's range | 82.50 - 112.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Motley Fool3 No-Brainer Stocks to Buy With $1,000 Right Now
A modest amount of money can go a long way when it's invested in highly profitable industry leaders with sustained competitive advantages.
Business WireVertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
BOSTON, October 03, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented longer-term data on patients dosed in Parts A and B of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). Prior to VX-880 treatment, all six patients enrolled had long-standing T1D with no endogenous insulin secretion, required
Motley Fool2 Top Biotech Stocks to Buy in October
Or you could invest in commercial stage companies that might be about to enter a new phase of growth. Vertex shares have climbed this year, but considering the biotech's prospects, the shares still have plenty of room to run. Vertex Pharmaceuticals is the leader in the world of cystic fibrosis (CF) treatment, and it expects this dominance to last into at least the late 2030s.
